Mitochondrial permeability transition pore as a target for cardioprotection in the human heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 1 58-1, 2005, Pages

  Shanmuganathan, Selvaraj ^a   Hausenloy, Derek J ^a   Duchen, Michael R ^b   Yellon, Derek M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Human cardiac muscle; Hypoxia reoxygenation

Indexed keywords

CYCLOSPORIN A; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; SANGLIFEHRIN A;

ARTICLE; CELL DEATH; CONTROLLED STUDY; HEART; HEART ATRIUM; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; OXIDATIVE STRESS; PRIORITY JOURNAL; REOXYGENATION;

ANOXIA; CARDIOTONIC AGENTS; CELL SURVIVAL; CYCLOSPORINE; HUMANS; ION CHANNELS; LACTONES; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; OXYGEN; SPIRO COMPOUNDS;

EID: 21644475173     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01192.2004     Document Type: Article

References (40)

1. Andree HA, Reutelingsperger CP, Hauptmann R, Hemker HC, Hermens WT, and Willems GM. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem 265: 4923-4928, 1990.
2. Bell SP, Sack MN, Patel A, Opie LH, and Yellon DM. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 36: 2296-2302, 2000.
3. 2+ and oxidative stress. FEBS Lett 304: 192-194, 1992.
4. Bunting JR, Phan TV, Kamali E, and Dowben RM. Fluorescent cationic probes of mitochondria. Metrics and mechanism of interaction. Biophys J 56: 979-993, 1989.
5. Carr CS, Grover GJ, Pugsley WB, and Yellon DM. Comparison of the protective effects of a highly selective ATP-sensitive potassium channel opener and ischemic preconditioning in isolated human atrial muscle. Cardiovasc Drugs Ther 11: 473-478, 1997.
6. Carr CS, Hill RJ, Masamune H, Kennedy SP, Knight DR, Tracey WR, and Yellon DM. Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc Res 36: 52-59, 1997.
7. Clarke SJ, McStay GP, and Halestrap AP. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem 277: 34793-34799, 2002.
8. Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, and Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96: 29-32, 1997.
9. + channel. J Mol Cell Cardiol 29: 175-182, 1997.
10. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 341: 233-249, 1999.
11. De Giorgi F, Lartigue L, Bauer MK, Schubert A, Grimm S, Hanson GT, Remington SJ, Youle RJ, and Ichas F. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J 16: 607-609, 2002.
12. + and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276: 2571-2575, 2001.
13. 2+ in cell physiology and pathophysiology. Cell Calcium 28: 339-348, 2000.
14. Duchen MR, Leyssens A, and Crompton M. Transient mitochondrial depolarizations reflect focal sarcoplasmic reticular calcium release in single rat cardiomyocytes. J Cell Biol 142: 975-988, 1998.
15. Ehrenberg B, Montana V, Wei MD, Wuskell JP, and Loew LM. Membrane potential can be determined in individual cells from the nernstian distribution of cationic dyes. Biophys J 53: 785-794, 1988.
16. Esumi K, Nishida M, Shaw D, Smith TW, and Marsh JD. NADH measurements in adult rat myocytes during simulated ischemia. Am J Physiol Heart Circ Physiol 260: H1743-H1752, 1991.
17. Foglieni C, Meoni C, and Davalli AM. Fluorescent dyes for cell viability: an application on prefixed conditions. Histochem Cell Biol 115: 223-229, 2001.
18. Griffiths EJ and Halestrap AP. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 25: 1461-1469, 1993.
19. Griffiths EJ and Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 307: 93-98, 1995.
20. Harding SE, Jones SM, O'Gara P, del Monte F, Vescovo G, and Poole-Wilson PA. Isolated ventricular myocytes from failing and non-failing human heart; the relation of age and clinical status of patients to isoproterenol response. J Mol Cell Cardiol 24: 549-564, 1992.
21. Hausenloy DJ, Duchen MR, and Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60: 617-625, 2003.
22. Hausenloy DJ, Maddock HL, Baxter GF, and Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55: 534-543, 2002.
23. Hausenloy DJ, Yellon DM, Mani-Babu S, and Duchen MR. Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 287: H841-H849, 2004.
24. Huser J and Blatter LA. Fluctuations in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. Biochem J 343: 311-317, 1999.
25. Ichas F, Jouaville LS, and Mazat JP. Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals. Cell 89: 1145-1153, 1997.
26. 2+ and sustained opening of the permeability transition pore. J Cell Sci 115: 1175-1188, 2002.
27. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, and Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 549: 513-524, 2003.
28. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, and Sollott SJ. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549, 2004.
29. Li Y, Johnson N, Capano M, Edwards M, and Crompton M. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J 383: 101-109, 2004.
30. 2+ overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res 89: 891-898, 2001.
31. Nazareth W, Yafei N, and Crompton M. Inhibition of anoxia-induced injury in heart myocytes by cyclosporin A. J Mol Cell Cardiol 23: 1351-1354, 1991.
32. Pastorino JG, Snyder JW, Serroni A, Hoek JB, and Farber JL. Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. J Biol Chem 268: 13791-13798, 1993.
33. Qian T, Nieminen AL, Herman B, and Lemasters JJ. Mitochondrial permeability transition in pH-dependent reperfusion injury to rat hepatocytes. Am J Physiol Cell Physiol 273: C1783-C1792, 1997.
34. Sanglier JJ, Quesniaux V, Fehr T, Hofmann H, Mahnke M, Memmert K, Schuler W, Zenke G, Gschwind L, Maurer C, and Schilling W. Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308I10. I. Taxonomy, fermentation, isolation and biological activity. J Antibiot (Tokyo) 52: 466-473, 1999.
35. Schneider A, Ad N, Izhar U, Khaliulin I, Borman JB, and Schwalb H. Protection of myocardium by cyclosporin A and insulin: in vitro simulated ischemia study in human myocardium. Ann Thorac Surg 76: 1240-1245, 2003.
36. Shiga Y, Onodera H, Matsuo Y, and Kogure K. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res 595: 145-148, 1992.
37. + channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 77: 1030-1035, 1995.
38. Uchino H, Elmer E, Uchino K, Li PA, He QP, Smith ML, and Siesjo BK. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Brain Res 812: 216-226, 1998.
39. Walker DM, Walker JM, Pugsley WB, Pattison CW, and Yellon DM. Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol 27: 1349-1357, 1995.
40. Yoshimoto T, Uchino H, He QP, Li PA, and Siesjo BK. Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal ischemia in the rat. Brain Res 899: 148-158, 2001.